Section 12
Chapter 11,068

Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment

Beckers, N.G.M.; Macklon, N.S.; Eijkemans, M.J.; Ludwig, M.; Felberbaum, R.E.; Diedrich, K.; Bustion, S.; Loumaye, E.; Fauser, B.C.J.M.

Journal of Clinical Endocrinology and Metabolism 88(9): 4186-4192


ISSN/ISBN: 0021-972X
PMID: 12970285
DOI: 10.1210/jc.2002-021953
Accession: 011067838

Download citation:  

Replacing GnRH agonist cotreatment for the prevention of a premature rise in LH during ovarian stimulation for in vitro fertilization (IVF) by the late follicular phase administration of GnRH antagonist may render supplementation of the luteal phase redundant, because of the known rapid recovery of pituitary function after antagonist cessation.

PDF emailed within 0-6 h: $19.90